Rare nerve damage after an immune cancer drug
Original title: Demyelination of the central nervous system and peripheral neuropathy associated with sintilimab treatment for lung adenocarcinoma: a case report.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is a report about one patient, not a new treatment.
The short version
One man had serious nerve and brain damage after an immune cancer drug.
What was studied. Doctors wrote up the case of one patient. He was a 47-year-old man with lung cancer that had spread to his brain.
What they found. He got an immune drug called sintilimab. After nine cycles, his legs felt tingly and weak. He was also confused for a short time. Tests showed damage to nerves and to the brain and spinal cord. Doctors stopped the drug and gave steroid medicine through a vein. His symptoms went away fast at first. He died within one month after the symptoms started.
What this means, and what it doesn't
What it could mean: Immune cancer drugs can rarely harm the nerves and the brain. If you take one, tell your care team about new weakness, tingling, or confusion. Report it right away.
What it doesn't mean: This is one patient's story, not a study. It does not show how often this happens. It does not mean the drug will do this to you. It is not a new treatment, and it is not a promise of a cure. Do not stop any medicine on your own.
Source: PubMed, July 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.